Biography

Dr. Natalya Serbina is a Senior Project Leader in Biology at TB Alliance, a nonprofit organization dedicated to developing new TB treatments. Her research interests include host-directed therapies (HDTs) for TB and she has contributed to the development of novel HDT strategies, including the use of sertraline, an antidepressant, to modulate the host's immune response and augment the efficacy of standard TB drugs. She is a member of the ITHEMYC consortium, which evaluates compounds targeting various host pathways to improve TB treatment outcomes.